Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001193805-25-000870·Flynn James E
Schedule 13G ownership disclosure
Vera Therapeutics Inc
Common Stock · CUSIP: 92337R101
Event date: 2025-06-06
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Deerfield Mgmt, L.P.
Shares: 3,348,117.00 · Class: 5.25%
- Deerfield Management Company, L.P.
Shares: 3,348,117.00 · Class: 5.25%
- Deerfield Partners, L.P.
Shares: 3,348,117.00 · Class: 5.25%
- James E. Flynn
Shares: 3,348,117.00 · Class: 5.25%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193805-25-000870
- Form type
- SCHEDULE 13G
- Filer
- Flynn James E
- CIK
- CIK 1352546
- Filed
- Jun 11, 2025
- Reporting period
- Jun 06, 2025
- Description
- Schedule 13G beneficial ownership